About Replimune
Replimune is a company based in Oxford (United Kingdom) founded in 2015 by Philip Astley-Sparke.. Replimune has raised $87 million across 3 funding rounds from investors including Atlas Venture, SVB Securities and Foresite Capital. The company has 479 employees as of March 31, 2024. Replimune offers products and services including Oncolytic Immunotherapies and Investigational Therapies. Replimune operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Oxford, United Kingdom
- Employees 479 as on 31 Mar, 2024
- Founders Philip Astley-Sparke
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Replimune Group, Inc.
-
Annual Revenue
$00as on Mar 31, 2024
-
Net Profit
$-247.3 M-14.6as on Mar 31, 2024
-
EBITDA
$-259.9 M-11.05as on Mar 31, 2024
-
Total Equity Funding
$87 M (USD)
in 3 rounds
-
Latest Funding Round
$55 M (USD), Series B
Sep 07, 2017
-
Investors
Atlas Venture
& 7 more
-
Employee Count
479
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Replimune
Replimune is a publicly listed company on the NASDAQ with ticker symbol REPL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Replimune
Replimune offers a comprehensive portfolio of products and services, including Oncolytic Immunotherapies and Investigational Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapies designed to kill tumors and enhance immune responses against cancer.
Agents for treating solid tumor cancers in trials as single or combined options.
Unlock access to complete
Unlock access to complete
Funding Insights of Replimune
Replimune has successfully raised a total of $87M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $55 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $55.0M
-
First Round
First Round
(01 Apr 2015)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2017 | Amount | Series B - Replimune | Valuation | Foresite Capital | |
| Sep, 2015 | Amount | Series A - Replimune | Valuation |
investors |
|
| Apr, 2015 | Amount | Seed - Replimune | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Replimune
Replimune has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Atlas Venture, SVB Securities and Foresite Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Replimune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Replimune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Replimune Comparisons
Competitors of Replimune
Replimune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Replimune
Frequently Asked Questions about Replimune
When was Replimune founded?
Replimune was founded in 2015.
Where is Replimune located?
Replimune is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Who is the current CEO of Replimune?
Philip Astley-Sparke is the current CEO of Replimune. They have also founded this company.
Is Replimune a funded company?
Replimune is a funded company, having raised a total of $87M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Apr 01, 2015.
How many employees does Replimune have?
As of Mar 31, 2024, the latest employee count at Replimune is 479.
What does Replimune do?
Replimune was founded in 2015 in Oxford, United Kingdom, as a biotechnology company focused on oncolytic immunotherapies. A pipeline is being developed to strengthen direct anti-tumor effects via selective virus replication and to amplify immune reactions against released tumor antigens. Programs are advanced through clinical trials, with early integration of checkpoint blockade planned. Operations center on oncology, aiming for rapid progression in therapeutic development.
Who are the top competitors of Replimune?
Replimune's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Replimune offer?
Replimune offers Oncolytic Immunotherapies and Investigational Therapies.
Is Replimune publicly traded?
Yes, Replimune is publicly traded on NASDAQ under the ticker symbol REPL.
Who are Replimune's investors?
Replimune has 8 investors. Key investors include Atlas Venture, SVB Securities, Foresite Capital, Redmile Group, and Forbion.
What is Replimune's ticker symbol?
The ticker symbol of Replimune is REPL on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.